NCT06041035View on ClinicalTrials.gov

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

QLS31905

Administered as an intravenous infusion.

DRUG

Nab paclitaxel

125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

DRUG

Gemcitabine

1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

DRUG

Oxaliplatin

85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

DRUG

Capecitabine

1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.

DRUG

Cisplatin

25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06041035 - A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter